# Hankang Capital

> Hankang Capital is a VC fund in Shanghai backing Health Care and Biotechnology. See 29 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shanghai, China
- Total investments: 29
- Last investment: Apr 2026
- Lead investor: 34%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/hankang-capital/

Hankang Capital is an investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 31% |
| Biotechnology | 8 | 28% |
| Pharmaceutical | 7 | 24% |
| Medical | 6 | 21% |
| Therapeutics | 5 | 17% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 8 | 28% |
| Series A | 5 | 17% |
| Series C | 2 | 7% |
| Seed | 1 | 3% |
| Series D | 1 | 3% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 15 | 52% |
| United States | 1 | 3% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Microtide Biotechnology | Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M | Series A | Apr 29, 2026 |  |
| Pinnacle Medicines | Pinnacle Medicines is a peptide drug discovery company that provides peptide modality for medical needs. | $89M | Series B | Mar 26, 2026 |  |
| Spurious | Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $35M | Seed | Jan 30, 2026 |  |
| Lingtai Biotechnology | Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs. | $28.4M | Series B | Dec 18, 2025 |  |
| Phrontline Biopharma | Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. | $60M | Seed | Nov 21, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $63M | Series B | Sep 21, 2025 |  |
| VelaVigo | VelaVigo is a start-up company engaged in macromolecular biopharmaceuticals. | $60M | Seed | Jul 28, 2025 |  |
| Leto Laboratories | Leto Laboratories is a manufacturer of protein products. |  | Series C | Jul 23, 2025 |  |
| Spurious | Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $27.8M | Angel | Jun 04, 2025 |  |
| AusperBio | AusperBio is a Phase II clinical-stage biopharmaceutical company dedicated to transforming hepatitis B treatment for a cure and advancing oligonucleotide therapeutics. Leveraging their innovative and proprietary Med-Oligo™ ASO platform with effective targeted delivery technologies, AusperBio strives to unleash the power of ASO therapeutics to treata wide range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases. | $50.3M | Series B | May 28, 2025 |  |

10 of 29 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 9 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 7 deals together
- [BioVenture](https://shizune.co/investors/profile/bioventure) — VC Fund, 4 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 4 deals together
- Lichen Capital — VC Fund, 4 deals together
- [Addor Capital](https://shizune.co/investors/profile/addor-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Hankang Capital invest in?

Hankang Capital invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series B and Series A stage. Most of the 29 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Hankang Capital last invest?

The most recent investment recorded for Hankang Capital closed in Apr 2026. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co